Disease Landscape and Forecast Insights

TNF-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira) are the mainstay of biological treatment for moderate to severe Crohn’s disease (CD), while newer biologics (i.e., Takeda’s…

Clarivate Epidemiology’s coverage of Crohn’s disease comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of Crohn’s disease comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of Crohn’s disease comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of Crohn’s disease comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of Crohn’s disease comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…

The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next decade. The well-established TNF-α inhibitors (e…

Children with Crohn’s disease (CD) have a more-complicated disease course compared with adult patients. However, similar to adult CD, the primary goal of the treatment of pediatric CD is to…

Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. The primary goal of CD treatment is to induce and…

Children with Crohn’s disease (CD) have a more-complicated disease course compared with adult patients. However, similar to adult CD, the primary goal of the treatment of pediatric CD is to…

TNF-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira) are the mainstay of biological treatment for moderate to severe Crohn’s disease (CD), while newer biologics (i.e., Takeda’s…

Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. The primary goal of CD treatment is to induce and…